Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

YS Biopharma Says PIKA COVID-19 Vaccine Offers Superior Immunogenicity

publication date: Mar 27, 2023

YS Biopharma, a Beijing company, released positive interim Phase II safety and immunogenicity data for its PIKA recombinant COVID-19 Vaccine. Data from the Phase II part of the Phase II/III trial showed the prophylactic/therapeutic vaccine met its primary and secondary immunogenicity endpoints. The clinical study evaluated the PIKA recombinant COVID-19 vaccine vs. inactivated COVID-19 vaccine. YS Biopharma, a maker of vaccines and therapeutic biologics for infectious diseases and cancer, recently merged with Summit Healthcare Acquisition, a SPAC, and it now trades on the NASDAQ exchange with a market value of $284 million. More details....

Stock Symbol: (NSDQ: YS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here